Ocugen, Inc.
Business
Ocugen is a late-stage biotechnology company developing gene therapies, biologics, cell therapies, and vaccines to treat inherited retinal diseases, blindness, and other serious conditions. The company's core platform uses modifier gene therapy technology, with lead candidates OCU400, OCU410, and OCU410ST in clinical development. Additional programs include OCU200 for diabetic and wet AMD, NeoCart for knee cartilage repair, and inhaled mucosal vaccines for COVID-19 and influenza. The company operates globally with development and manufacturing partnerships.
Summary from 10-K filed 2026-03-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 4 | 4 | 6 | 2 | — | |
| Research and development | 40 | 32 | 40 | — | — | |
| General and administrative | 28 | 27 | 32 | 35 | 23 | |
| Total operating expenses | 67 | 59 | 72 | 92 | 58 | |
| Loss from operations | −63 | −55 | −66 | −89 | −58 | |
| Interest income | 900,000 | 1 | — | — | — | |
| Interest expense | −5 | −688,000 | — | — | — | |
| Other (expense) income, net | −664,000 | 140,000 | — | — | −310,000 | |
| Total other (expense) income | −5 | 703,000 | 2 | 2 | −389,000 | |
| Net loss | −68 | −54 | −63 | −87 | −58 | |
| Foreign currency translation adjustment | 13,000 | 28,000 | −5,000 | 25,000 | 0 | |
| Comprehensive loss | −68 | −54 | −63 | −87 | −58 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2023 2023-06-30 |
|---|---|---|---|---|---|---|
| Cash | 19 | 59 | 39 | — | — | |
| Prepaid expenses and other current assets | 6 | 3 | 4 | 3 | 3 | |
| Total current assets | 24 | 62 | 43 | 57 | 73 | |
| Property and equipment, net | 14 | 17 | 17 | 14 | 12 | |
| Restricted cash | 316,000 | 307,000 | 0 | — | — | |
| Other assets | 4 | 4 | 4 | 4 | 4 | |
| Total assets | 44 | 82 | 65 | 75 | 89 | |
| Accounts payable | 6 | 4 | 3 | 3 | 4 | |
| Accrued expenses and other current liabilities | 15 | 16 | 13 | 15 | 19 | |
| Operating lease obligations | 858,000 | 519,000 | 574,000 | 540,000 | 526,000 | |
| Current portion of long term debt | 1 | 1 | 0 | — | — | |
| Total current liabilities | 23 | 22 | 17 | 20 | 24 | |
| Operating lease obligations, less current portion | 3 | 3 | 4 | 3 | 3 | |
| Long term debt, net | 28 | 27 | 3 | 1 | 1 | |
| Other non-current liabilities | 2 | 564,000 | 527,000 | 497,000 | 455,000 | |
| Total non-current liabilities | 33 | 31 | 7 | 5 | 5 | |
| Total liabilities | 56 | 53 | 24 | 25 | 30 | |
| Commitments and contingencies (Note 16) | — | — | — | — | — | |
| Series B Convertible Preferred Stock; zero shares issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 1,000 | — | — | |
| Common stock; $0.01 par value; 390,000,000 shares authorized; 312,501,472 and 291,489,058 shares issued, and 312,379,972 and 291,367,558 shares outstanding at December 31, 2025 and 2024, respectively | 3 | 3 | 3 | 3 | 3 | |
| Treasury stock, at cost, 121,500 shares at December 31, 2025 and 2024 | −48,000 | −48,000 | −48,000 | −48,000 | −48,000 | |
| Additional paid-in capital | 393 | 367 | 324 | 322 | 320 | |
| Accumulated other comprehensive income | 61,000 | 48,000 | 20,000 | 27,000 | 22,000 | |
| Accumulated deficit | −408 | −340 | −286 | −275 | −263 | |
| Total stockholders' equity | −12 | 30 | 41 | 50 | 59 | |
| Total liabilities and stockholders' equity | 44 | 82 | 65 | 75 | 89 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization expense | 2 | 2 | 704,000 | 480,000 | — | |
| Amortization of Debt Issuance Costs | 1 | 16,000 | — | — | — | |
| Non-cash interest expense | 100,000 | 100,000 | 116,000 | 83,000 | 78,000 | |
| Non-cash lease expense | 1 | 856,000 | 538,000 | — | — | |
| Non-cash expense (income) from collaborative arrangements, net | −2 | −2 | — | — | — | |
| Stock-based compensation expense | 8 | 7 | 9 | 11 | 7 | |
| Other | 1 | 37,000 | 46,000 | −671,000 | 26,000 | |
| Prepaid expenses and other current assets | −3 | 361,000 | −296,000 | 91,000 | −742,000 | |
| Accounts payable and accrued expenses | 3 | 4 | −12 | 9 | 3 | |
| Lease obligations | −1 | −833,000 | −517,000 | −383,000 | −366,000 | |
| Net cash used in operating activities | −57 | −42 | −62 | −60 | −48 | |
| Purchases of property and equipment | −185,000 | −3 | −10 | −4 | −939,000 | |
| Payment of security deposits | −126,000 | 0 | — | — | — | |
| Net cash (used in) provided by investing activities | −311,000 | −3 | 3 | −17 | −2 | |
| Proceeds from issuance of common stock | 20 | 39 | 21 | 60 | 129 | |
| Payment of equity issuance costs | −2 | −3 | −355,000 | −549,000 | −9 | |
| Proceeds from issuance of debt | 0 | 30 | 500,000 | 500,000 | — | |
| Payments of debt issuance costs | 0 | −809,000 | −68,000 | −43,000 | 0 | |
| Payment of EB-5 loan | −1 | 0 | — | — | — | |
| Net cash provided by financing activities | 17 | 65 | 21 | 59 | 121 | |
| Effect of changes in exchange rate on cash and restricted cash | 13,000 | 28,000 | −5,000 | 25,000 | 0 | |
| Net (decrease) increase in cash and restricted cash | −40 | 19 | −38 | −18 | 71 | |
| Right-of-use assets related to operating leases | 1 | 103,000 | 572,000 | — | — | |
| Series B Convertible Preferred Stock reacquisition | 0 | −1,000 | 0 | — | — | |
| Issuance of common stock for Avenue Capital agreement | 0 | 1 | 0 | — | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Ocugen, Inc.'s CIK number?
Ocugen, Inc.'s SEC CIK number is 0001372299 (1372299). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Ocugen, Inc.'s SEC filings?
All of Ocugen, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Ocugen, Inc. last report earnings?
Ocugen, Inc. (OCGN) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-057138). This is Ocugen, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Ocugen, Inc.'s most recent earnings 8-K?
Ocugen, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001104659-26-057138. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Ocugen, Inc.'s latest earnings 8-K →
Look up any company's CIK number →